IMPACT OF NEXTSENSE INSTITUTE RESEARCH IN THE FIELD OF SENSORY DISABILITIES
With
Professor Greg Leigh AO,
Director, NextSense Institute, Australia &
Conjoint Professor,
Macquarie School of Education
Macquarie University, Sydney
RESEARCH IMPACT
Filmed in Sydney, Australia | June 2025
NextSense, formerly known as the Royal Institute for Deaf & Blind Children, is a not-for-profit established in 1860 that provides dedicated, innovative, and customised services aimed at breaking down barriers for children, adults and families of people with hearing or vision loss.
NextSense has a 165 year history of providing services and education for individuals with sensory impairments. With the support of donations, NextSense provides vital support for children and adults, more cochlear implants than any other service in Australia, and is a world leader for research, technology and professional education in the fields of visions and hearing loss.
NextSense clinicians are actively involved in a number of leading research projects—both independently and in collaboration with local and international organisations.
The NextSense Institute, part of NextSense is Australia’s leading centre for research and professional education in the field of sensory disabilities.
The Institute offers a range of educational programs, including postgraduate degrees, professional development courses, and customised training for educators, therapists, health professionals, and carers. One of its flagship programs is the Master of Disability Studies, delivered in affiliation with Macquarie University, which prepares professionals to work with individuals who are deaf, hard of hearing, blind, or have low vision.
Professor Greg Leigh AO, Director NextSense Institute, talks about 3 areas of research that have had significant impact in it’s delivery of programs and services to Australians and countries across the world.
Through this research, NextSense Institute aims to break down barriers and redefine what is possible for individuals with sensory disabilities, fostering inclusion and enhancing quality of life.
Source: Written by AUDIENCED using source information from the NextSense website
-
Role of metabolic dysfunction in advanced prostate cancer
Dr Gunter was drawn to the area of prostate cancer research and the intersection between chronic metabolic disorders and their emerging relationship to cancer. Her strengths include expertise in the metabolic syndrome, insulin signalling and metabolism, and she has a demonstrated record of successful and productive research projects in metabolic research where she now applies her efforts to understanding the role of metabolic dysfunction in advanced prostate cancer.
-
Big data to improve the use of antidepressant medicines in aged care
Georgina Hughes is a pharmacist & PhD Candidate with the University of South Australia Clinical and Health Sciences and the Registry of Senior Australians (ROSA), undertaking research at South Australian Health and Medical Research Institute (SAHMRI).
Georgina’s PhD study and first published paper was on how to improve the safe and effective use of antidepressant medicines and optimise quality use of medicines in older people accessing residential aged care.
-
Targeting chemotherapy resistance in ovarian cancer patients
Dr Alex Cole, from the Centenary Institute’s Centre for Biomedical AI, is now leading the research focused on developing a new treatment to counteract a protein called follistatin (FST), known for making ovarian cancer cells resistant to chemotherapy.
By employing cutting-edge molecular biology and directed evolution techniques, the project aims to create nanobodies—small, precise molecules—that can block FST. If successful, these nanobodies could enhance the effectiveness of chemotherapy and improve ovarian cancer treatment rates.
